<DOC>
	<DOCNO>NCT01449773</DOCNO>
	<brief_summary>The overaccumulation apoB-48-containing lipoproteins intestinal origin see patient type 2 diabetes think attributable elevated intestinal production reduce clearance . Substantial evidence exists indicate elevate plasma level lipoproteins associate increase cardiovascular disease risk . Therefore , reduction atherogenic plasma triglyceride-rich lipoprotein ( TRL ) level intestinal origin appear crucial improve CVD risk associate type 2 diabetes . In regard , n-3 PUFAs show exert beneficial effect diabetic dyslipidemia . However , investigator understand physiological change occur n-3 PUFA supplementation suboptimal , thereby limit investigator appreciation impact CVD risk associate type 2 diabetes . The effect n-3 PUFAs intestinal production TRLs expression gene regulate intestinal lipid absorption chylomicron synthesis yet examine human . The general objective propose research investigate mechanisms n-3 PUFAs beneficially modify intestinal lipoprotein metabolism patient type 2 diabetes . The investigator hypothesize n-3 PUFA supplementation men type 2 diabetes : - reduce TRL apoB-48 production rate increase fractional catabolic rate lipoprotein , - decrease expression gene regulate intestinal lipid absorption synthesis well synthesis apoB-48-containing lipoprotein , - decrease plasma surrogates cholesterol absorption cholesterol synthesis .</brief_summary>
	<brief_title>Effects N-3 Polyunsaturated Fatty Acids On Chylomicron Secretion And Expression Of Genes That Regulate Intestinal Lipid Metabolism In Men With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>age 18 55 year , plasma TG level 50th percentile age , nonsmoker , BMI 25.0 40.0 kg/m2 , stable body weight least 6 month prior study baseline , HbA1c 6.5 8.5 % , baseline fast plasma glucose &lt; 15.0 mmol/L patient de novo type 2 diabetes take oral hypoglycemic agent patient receive stable dos metformin least 3 month randomization . extreme dyslipidemias familial hypercholesterolemia , patient secondary form diabetes acute metabolic diabetic complication , patient receive treated insulin thiazolidinedione within past 6 month , subject CVD ( CHD , cerebrovascular disease peripheral arterial disease ) subject taking medication know affect lipoprotein metabolism ( e.g . steroid , beta blocker , thiazide diuretic , lipid lower agent , significant alcohol intake</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>